Wellinks
Wellinks Announces $10M First Close of Series B Funding
Wellinks announced $10M in Series B financing on August 4, 2026. Wellinks announced the first close of a $10 million Series B with participation from UMass Memorial Health and inside investors to fund commercial growth in cardiopulmonary care.
Round details
The financing includes backing from UMass Memorial Health. The company did not publish a valuation with the announcement.
- Round: Series B
- Capital announced: $10M
How the company plans to use the capital
Wellinks said it will use the funding to extend cardiopulmonary care to broader patient populations, including rural and underserved communities, strengthen its predictive capabilities using real-world clinical data, and expand into additional cardiopulmonary conditions, including congestive heart failure.
Why this matters for GTM teams
The release describes the investment as building on Wellinks’ strategic partnership with UMass Memorial Health and other commercial partners, and it does not name the inside investors.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Wellinks Series B announcement.
Company Info
Investors (1)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started